A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Gaboxadol

Criteria

Inclusion Criteria:

• patients with a diagnosis of primary insomnia